The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator ...

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make ...

When bladder cancer invades nearby muscle, total removal of the organ is the standard of care A new trial finds that post-op ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck's Keytruda (pembrolizumab ... Thus these two ...